PMID- 34974809
OWN - NLM
STAT- MEDLINE
DCOM- 20220223
LR  - 20240220
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 13
IP  - 1
DP  - 2022 Jan
TI  - Long non-coding RNA HOXA11 antisense RNA upregulates spermatogenesis-associated 
      serine-rich 2-like to enhance cisplatin resistance in laryngeal squamous cell 
      carcinoma by suppressing microRNA-518a.
PG  - 974-984
LID - 10.1080/21655979.2021.2016038 [doi]
AB  - Long noncoding RNAs (LncRNAs) are closely associated with the chemoresistance of 
      laryngeal squamous cell carcinoma (LSCC). Previous studies indicated that 
      HOXA11-AS could function as a vital regulator in human cancers. However, the 
      regulatory mechanisms of HOXA11-AS in the chemoresistance of LSCC remain unclear. 
      In this study, it was found that HOXA11-AS expression was upregulated in 
      cisplatin (CDDP)-resistant LSCC tissues and cells. Loss-of-function assays 
      revealed that HOXA11-AS knockdown inhibited the viability, migration, and 
      invasion, but promoted the apoptosis of CDDP-resistant LSCC cells. Meanwhile, we 
      identified miR-518a as a downstream gene of HOXA11-AS in LSCC, and miR-518a 
      silencing reversed the promotive effect of HOXA11-AS knockdown on CDDP 
      sensitivity of LSCC cells. In addition, miR-518a could inhibit 
      spermatogenesis-associated serine-rich 2-like (SPATS2L) expression by direct 
      interaction, and upregulation of SPATS2L abrogated the inhibitory effect of 
      HOXA11-AS silencing or miR-518a overexpression on CDDP resistance of 
      CDDP-resistant LSCC cells. In sum, our results demonstrated that HOXA11-AS 
      enhanced CDDP resistance of LSCC via miR-518a/SPATS2L axis, which might offer 
      novel therapeutic strategies for CDDP-resistant LSCC.
FAU - Shen, Na
AU  - Shen N
AD  - The Department of Otolaryngology Head and Neck Surgery, Tianjin Children's 
      Hospital, Tianjin, China.
FAU - Duan, Xiaohui
AU  - Duan X
AUID- ORCID: 0000-0001-7102-3646
AD  - The Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of 
      Hebei Engineering University, Handan, Hebei, China.
FAU - Feng, Yong
AU  - Feng Y
AD  - The Department of Otolaryngology Head and Neck Surgery, The 4th Central Hospital 
      of Tianjin, Tianjin, China.
FAU - Zhang, Jianxin
AU  - Zhang J
AD  - The Department of Otolaryngology Head and Neck Surgery, The 4th Central Hospital 
      of Tianjin, Tianjin, China.
FAU - Qiao, Xiaocheng
AU  - Qiao X
AD  - The Department of Otolaryngology Head and Neck Surgery, The 4th Central Hospital 
      of Tianjin, Tianjin, China.
FAU - Ding, Wenyu
AU  - Ding W
AD  - The Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of 
      Hebei Engineering University, Handan, Hebei, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Retracted Publication
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 (MIRN518 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Proteins)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (SPATS2L protein, human)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
RIN - Bioengineered. 2024 Dec;15(1):2299591. PMID: 38376870
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Cell Survival
MH  - Cisplatin/pharmacology
MH  - *Drug Resistance, Neoplasm
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics
MH  - MicroRNAs/*genetics
MH  - Proteins/*genetics
MH  - RNA, Long Noncoding/genetics
MH  - Squamous Cell Carcinoma of Head and Neck/*genetics
MH  - Up-Regulation
PMC - PMC8805888
OTO - NOTNLM
OT  - HOXA11-AS
OT  - SPATS2L
OT  - laryngeal squamous cell carcinoma
OT  - miR-518a
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/01/04 06:00
MHDA- 2022/02/24 06:00
PMCR- 2022/01/03
CRDT- 2022/01/03 05:21
PHST- 2022/01/03 05:21 [entrez]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/02/24 06:00 [medline]
PHST- 2022/01/03 00:00 [pmc-release]
AID - 2016038 [pii]
AID - 10.1080/21655979.2021.2016038 [doi]
PST - ppublish
SO  - Bioengineered. 2022 Jan;13(1):974-984. doi: 10.1080/21655979.2021.2016038.